Yun Gee Young, Kim Seok Hyun, Kim Seok Won, Joo Jong Seok, Kim Ju Seok, Lee Eaum Seok, Lee Byung Seok, Kang Sun Hyoung, Moon Hee Seok, Sung Jae Kyu, Lee Heon Young, Kim Kyung Hee
Gee Young Yun, Seok Hyun Kim, Seok Won Kim, Jong Seok Joo, Ju Seok Kim, Eaum Seok Lee, Byung Seok Lee, Sun Hyoung Kang, Hee Seok Moon, Jae Kyu Sung, Heon Young Lee, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon 301-721, South Korea.
World J Gastroenterol. 2016 Apr 21;22(15):4062-5. doi: 10.3748/wjg.v22.i15.4062.
Anti-androgen therapy is the leading treatment for advanced prostate cancer and is commonly used for neoadjuvant or adjuvant treatment. Bicalutamide is a non-steroidal anti-androgen, used during the initiation of androgen deprivation therapy along with a luteinizing hormone-releasing hormone agonist to reduce the symptoms of tumor-related flares in patients with advanced prostate cancer. As side effects, bicalutamide can cause fatigue, gynecomastia, and decreased libido through competitive androgen receptor blockade. Additionally, although not as common, drug-induced liver injury has also been reported. Herein, we report a case of hepatotoxicity secondary to bicalutamide use. Typically, bicalutamide-induced hepatotoxicity develops after a few days; however, in this case, hepatic injury occurred 5 mo after treatment initiation. Based on this rare case of delayed liver injury, we recommend careful monitoring of liver function throughout bicalutamide treatment for prostate cancer.
抗雄激素疗法是晚期前列腺癌的主要治疗方法，常用于新辅助或辅助治疗。比卡鲁胺是一种非甾体类抗雄激素药物，在雄激素剥夺治疗开始时与促黄体生成素释放激素激动剂联合使用，以减轻晚期前列腺癌患者肿瘤相关症状的发作。作为副作用，比卡鲁胺可通过竞争性雄激素受体阻断导致疲劳、男性乳房发育和性欲减退。此外，虽然不太常见，但也有药物性肝损伤的报道。在此，我们报告一例比卡鲁胺使用继发肝毒性的病例。通常，比卡鲁胺引起的肝毒性在数天后出现；然而，在本病例中，肝损伤发生在治疗开始后5个月。基于这一罕见的延迟性肝损伤病例，我们建议在比卡鲁胺治疗前列腺癌的全过程中仔细监测肝功能。
